Physician profile
Catvan Le
NPI 1457593477
$3,347.36
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,020 · 2020: $1,109 · 2021: $1,108 · 2022: $111.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $440.08 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $311.89 | 2019-2021 | |
| Allergan, INC. | $288.55 | 2019-2021 | |
| Nuvasive, INC. | $256.42 | 2021 | |
| Nevro Corp. | $216.33 | 2019-2022 | |
| Medtronic, INC. | $200.62 | 2021 | |
| Scilex Pharmaceuticals INC. | $186.99 | 2019-2021 | |
| Tersera Therapeutics LLC | $175.62 | 2019-2020 | |
| Si-Bone, INC. | $148.55 | 2019 | |
| Abbott Laboratories | $143.62 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $133.90 | 2019-2022 | |
| Medtronic USA, INC. | $123.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $122.62 | 2019-2021 | |
| Lilly USA, LLC | $98.89 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $85.04 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $56.47 | 2020 | |
| Zyla Life Sciences, INC. | $56.21 | 2019-2020 | |
| Redhill Biopharma INC. | $42.99 | 2020-2021 | |
| Mdd US Operations, LLC | $38.06 | 2020 | |
| Flowonix Medical Incorporated | $37.98 | 2019 | |
| Almatica Pharma LLC | $29.79 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.83 | 2019-2021 | |
| Shionogi INC | $27.90 | 2019 | |
| Horizon Therapeutics Plc | $27.34 | 2021-2022 | |
| Baudax Bio INC. | $15.00 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $15.00 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.58 | 2021 | |
| Grt US Holding, INC. | $12.93 | 2020 | |
| Fidia Pharma USA INC. | $12.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catvan Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.